## Jorge S Reis-Filho

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8602794/publications.pdf

Version: 2024-02-01

169 papers 19,602 citations

67 h-index 134 g-index

172 all docs

172 docs citations

172 times ranked

25750 citing authors

#	Article	IF	CITATIONS
1	Genomic characterization of small cell carcinomas of the uterine cervix. Molecular Oncology, 2022, 16, 833-845.	4.6	14
2	Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion 130. Journal of the National Cancer Institute, 2022, 114, 664-675.	6.3	31
3	The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features. Modern Pathology, 2022, 35, 193-201.	<b>5.</b> 5	25
4	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. Clinical Cancer Research, 2022, 28, 404-413.	7.0	13
5	Stromal <i>MED12</i> exon 2 mutations in complex fibroadenomas of the breast. Journal of Clinical Pathology, 2022, 75, 133-136.	2.0	2
6	Pathogenesis of Triple-Negative Breast Cancer. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 181-204.	22.4	132
7	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. Journal of the National Cancer Institute, 2022, 114, 761-770.	6.3	3
8	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
9	Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression. Oncogene, 2022, 41, 1835-1850.	5.9	9
10	Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. Gynecologic Oncology, 2022, 165, 239-247.	1.4	9
11	Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100365.	3.0	1
12	Genomic landscape of endometrial carcinomas of no specific molecular profile. Modern Pathology, 2022, 35, 1269-1278.	5.5	33
13	Recurrent <i>WWTR1</i> <scp>S89W</scp> mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix. Journal of Pathology, 2022, 257, 635-649.	4.5	2
14	LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer. Npj Breast Cancer, 2022, 8, 49.	5.2	4
15	Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers. Npj Breast Cancer, 2022, 8, 51.	5.2	9
16	Delivering precision oncology to patients with cancer. Nature Medicine, 2022, 28, 658-665.	30.7	125
17	Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. Nature Cancer, 2022, 3, 723-733.	13.2	82
18	Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. Journal of the National Cancer Institute, 2021, 113, 266-273.	6.3	38

#	Article	IF	CITATIONS
19	Problematic breast tumors reassessed in light of novel molecular data. Modern Pathology, 2021, 34, 38-47.	5.5	25
20	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. Molecular Oncology, 2021, 15, 1024-1039.	4.6	21
21	<scp>Wholeâ€exome</scp> sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. Journal of Pathology: Clinical Research, 2021, 7, 113-120.	3.0	4
22	Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations. Modern Pathology, 2021, 34, 1213-1225.	5.5	28
23	Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes. Modern Pathology, 2021, 34, 994-1007.	5.5	19
24	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. Histopathology, 2021, 78, 759-771.	2.9	13
25	A Distinctive Adnexal (Usually Paratubal) Neoplasm Often Associated With Peutz-Jeghers Syndrome and Characterized by STK11 Alterations (STK11 Adnexal Tumor). American Journal of Surgical Pathology, 2021, 45, 1061-1074.	3.7	19
26	Ultraviolet radiation drives mutations in a subset of mucosal melanomas. Nature Communications, 2021, 12, 259.	12.8	27
27	Homologous recombination deficiency: how genomic signatures are generated. Current Opinion in Genetics and Development, 2021, 66, 93-100.	3.3	13
28	Genomic Alterations in <i>PIK3CA</i> -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors. Cancer Research, 2021, 81, 2470-2480.	0.9	20
29	Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases. Modern Pathology, 2021, 34, 1570-1587.	5.5	57
30	Genomic profile of advanced breast cancer in circulating tumour DNA. Nature Communications, 2021, 12, 2423.	12.8	54
31	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. Npj Breast Cancer, 2021, 7, 43.	5.2	16
32	Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development. Npj Breast Cancer, 2021, 7, 45.	5.2	7
33	Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma. Histopathology, 2021, 79, 176-186.	2.9	4
34	Independent realâ€world application of a clinicalâ€grade automated prostate cancer detection system. Journal of Pathology, 2021, 254, 147-158.	4.5	57
35	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. Gynecologic Oncology, 2021, 161, 535-544.	1.4	16
36	PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays. American Journal of Surgical Pathology, 2021, 45, 1274-1281.	3.7	6

#	Article	IF	CITATIONS
37	Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes. Modern Pathology, 2021, 34, 1850-1859.	5.5	3
38	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. Npj Breast Cancer, 2021, 7, 96.	5.2	38
39	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. Journal of the National Cancer Institute, 2021, , .	6.3	6
40	Diagnosis and management of an endometrial cancer patient with Cowden syndrome. Gynecologic Oncology, 2021, 163, 14-21.	1.4	6
41	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. Npj Breast Cancer, 2021, 7, 124.	5.2	7
42	Spectrum of <i>BRAF</i> Mutations and Gene Rearrangements in Ovarian Serous Carcinoma. JCO Precision Oncology, 2021, 5, 1480-1492.	3.0	8
43	Ki67 Assessment in Breast Cancer: Are We There Yet?. Journal of the National Cancer Institute, 2021, 113, 797-798.	6.3	7
44	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. Npj Breast Cancer, 2021, 7, 135.	5.2	9
45	HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nature Communications, 2021, 12, 6667.	12.8	47
46	Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature, 2021, 599, 679-683.	27.8	183
47	Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas. Modern Pathology, 2021, , .	5.5	3
48	ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment. Modern Pathology, 2021, , .	<b>5.</b> 5	5
49	Sclerosing epithelioid mesenchymal neoplasm of the pancreas–Âa proposed new entity. Modern Pathology, 2020, 33, 456-467.	5.5	10
50	Histologic spectrum of polymorphous adenocarcinoma of the salivary gland harbor genetic alterations affecting PRKD genes. Modern Pathology, 2020, 33, 65-73.	5.5	29
51	Immunohistochemical assessment of HRASQ61R mutations in breast adenomyoepitheliomas. Histopathology, 2020, 76, 865-874.	2.9	19
52	Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. Nature Communications, 2020, 11, 44.	12.8	34
53	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. Modern Pathology, 2020, 33, 1056-1064.	5.5	35
54	Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. JCO Precision Oncology, 2020, 4, 1217-1223.	3.0	1

#	Article	IF	Citations
55	The genomic landscape of metastatic histologic special types of invasive breast cancer. Npj Breast Cancer, 2020, 6, 53.	<b>5.</b> 2	27
56	Wholeâ€exome analysis of metaplastic breast carcinomas with extensive osseous differentiation. Histopathology, 2020, 77, 321-326.	2.9	7
57	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nature Cancer, 2020, 1, 1188-1203.	13.2	114
58	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. Cancer Cell, 2020, 38, 534-550.e9.	16.8	67
59	Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG). American Journal of Surgical Pathology, 2020, 44, 545-552.	3.7	39
60	Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nature Genetics, 2020, 52, 582-593.	21.4	136
61	Oncogenic properties and signaling basis of the PAX8â€GLIS3 fusion gene. International Journal of Cancer, 2020, 147, 2253-2264.	5.1	10
62	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	5.2	106
63	Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes. Npj Breast Cancer, 2020, 6, 20.	5.2	25
64	Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary. Modern Pathology, 2020, 33, 1606-1617.	5 <b>.</b> 5	38
65	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. Modern Pathology, 2020, 33, 2221-2232.	5.5	23
66	ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nature Genetics, 2020, 52, 198-207.	21.4	140
67	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer, 2020, 1, 382-393.	13.2	96
68	Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma <i>In Situ</i> to Invasive Ductal Carcinoma. Clinical Cancer Research, 2020, 26, 3682-3693.	7.0	42
69	Homologous recombination DNA repair defects in PALB2-associated breast cancers. Npj Breast Cancer, 2019, 5, 23.	5.2	39
70	How Did We Get There? The Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma. Current Breast Cancer Reports, 2019, 11, 175-184.	1.0	0
71	Wholeâ€exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. Histopathology, 2019, 75, 931-937.	2.9	16
72	PAX8–GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. Modern Pathology, 2019, 32, 1734-1743.	<b>5.</b> 5	38

#	Article	IF	Citations
73	Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas. Npj Breast Cancer, 2019, 5, 6.	5.2	21
74	V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. Cancer Discovery, 2019, 9, 1182-1191.	9.4	27
75	Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential. Histopathology, 2019, 75, 213-224.	2.9	46
76	Genomic analysis of recurrences and highâ€grade forms of polymorphous adenocarcinoma. Histopathology, 2019, 75, 193-201.	2.9	10
77	Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma. Histopathology, 2019, 75, 139-145.	2.9	22
78	Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway. Molecular Oncology, 2019, 13, 1684-1692.	4.6	21
79	Massively parallel sequencing analysis of benign melanocytic naevi. Histopathology, 2019, 75, 29-38.	2.9	12
80	Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. Scientific Reports, $2019, 9, 16830$ .	3.3	29
81	Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer. JCO Precision Oncology, 2019, 3, 1-9.	3.0	10
82	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine, 2019, 25, 1928-1937.	30.7	485
83	Endometrial Cancers in <i>BRCA1</i> or <i>BRCA2</i> Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. JCO Precision Oncology, 2019, 3, 1-11.	3.0	19
84	The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma. Modern Pathology, 2019, 32, 205-215.	5.5	22
85	Lobular Carcinomas <i>In Situ</i> Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. Clinical Cancer Research, 2019, 25, 674-686.	7.0	44
86	Somatic genetic alterations in synchronous and metachronous lowâ€grade serous tumours and highâ€grade carcinomas of the adnexa. Histopathology, 2019, 74, 638-650.	2.9	11
87	Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. Gynecologic Oncology, 2019, 152, 11-19.	1.4	66
88	Recurrent <i>MED12</i> exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults. Journal of Clinical Pathology, 2019, 72, 258-262.	2.0	22
89	The Genomic Landscape of Mucinous Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 737-741.	6.3	68
90	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. Journal of the National Cancer Institute, 2018, 110, 1030-1034.	6.3	90

#	Article	IF	Citations
91	Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. Cancer Research, 2018, 78, 3112-3121.	0.9	57
92	Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting $\langle i \rangle < cp \rangle DH <  scp \rangle 2 <  i \rangle $ and $\langle i \rangle < cp \rangle PIK <  scp \rangle 3 < scp \rangle CA <  scp \ <  i \cdot : a validation cohort. Histopathology, 2018, 73, 339-344.$	2.9	44
93	Invasion in breast lesions: the role of the epithelial–stroma barrier. Histopathology, 2018, 72, 1075-1083.	2.9	25
94	<i>MYBL1</i> rearrangements and <i>MYB</i> amplification in breast adenoid cystic carcinomas lacking the <i>MYB</i> – <i>NFIB</i> fusion gene. Journal of Pathology, 2018, 244, 143-150.	4.5	74
95	Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity. Cell Reports, 2018, 25, 1446-1457.	6.4	76
96	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, 2018, 34, 893-905.e8.	16.8	307
97	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	16.8	633
98	Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nature Communications, 2018, 9, 3533.	12.8	92
99	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nature Communications, 2018, 9, 1816.	12.8	105
100	Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications. Current Breast Cancer Reports, 2017, 9, 34-44.	1.0	11
101	Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. Nature Medicine, 2017, 23, 376-385.	30.7	111
102	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. Clinical Cancer Research, 2017, 23, 3859-3870.	7.0	129
103	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. Histopathology, 2017, 71, 480-487.	2.9	2
104	Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesisâ€generating study. Histopathology, 2017, 71, 626-634.	2.9	26
105	Genetic Heterogeneity in Therapy-Na $\tilde{A}$ -ve Synchronous Primary Breast Cancers and Their Metastases. Clinical Cancer Research, 2017, 23, 4402-4415.	7.0	91
106	Biâ€ellelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. Journal of Pathology, 2017, 242, 165-177.	4.5	43
107	Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nature Communications, 2017, 8, 857.	12.8	182
108	Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways. Npj Breast Cancer, 2017, 3, 40.	5.2	52

#	Article	IF	Citations
109	Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis. International Journal of Gynecological Pathology, 2017, 36, 76-89.	1.4	26
110	The Spectrum of Triple-Negative Breast Disease. American Journal of Pathology, 2017, 187, 2139-2151.	3.8	118
111	An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. Nature Medicine, 2017, 23, 929-937.	30.7	146
112	Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. Npj Breast Cancer, 2017, 3, 48.	5.2	63
113	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. Modern Pathology, 2017, 30, 69-84.	5.5	48
114	Lack of <i>&gt;<scp>PRKD</scp>2</i> > and <i>&gt;<scp>PRKD</scp>3</i> > kinase domain somatic mutations in <i>&gt;<scp>PRKD</scp>PRKD1</i> > wildâ€type classic polymorphous lowâ€grade adenocarcinomas of the salivary gland. Histopathology, 2016, 68, 1055-1062.	2.9	23
115	Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile. Histopathology, 2016, 68, 1030-1039.	2.9	31
116	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <i><scp>TERT</scp></i> promoter hotspot mutations and <i>TERT</i> gene amplification as likely drivers of progression. Journal of Pathology, 2016, 238, 508-518.	4.5	102
117	Microglandular adenosis associated with tripleâ€negative breast cancer is a neoplastic lesion of tripleâ€negative phenotype harbouring <i><scp>TP53</scp></i> somatic mutations. Journal of Pathology, 2016, 238, 677-688.	4.5	52
118	Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. Histopathology, 2016, 68, 262-271.	2.9	22
119	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
120	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer and Metastasis Reviews, 2016, 35, 547-573.	5.9	189
121	Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. Npj Breast Cancer, 2016, 2, 16035.	5.2	28
122	<i>IDH2</i> Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. Cancer Research, 2016, 76, 7118-7129.	0.9	99
123	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Modern Pathology, 2016, 29, 476-488.	5 <b>.</b> 5	95
124	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clinical Cancer Research, 2016, 22, 4623-4633.	7.0	153
125	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. Modern Pathology, 2016, 29, 1292-1305.	<b>5.</b> 5	68
126	Phyllodes tumours of the breast: a consensus review. Histopathology, 2016, 68, 5-21.	2.9	329

#	Article	IF	Citations
127	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. Npj Breast Cancer, 2016, 2, 16036.	5.2	127
128	Uterine adenosarcomas are mesenchymal neoplasms. Journal of Pathology, 2016, 238, 381-388.	4.5	94
129	The Genomic Landscape of Male Breast Cancers. Clinical Cancer Research, 2016, 22, 4045-4056.	7.0	119
130	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesisâ€generating study. Journal of Pathology, 2015, 237, 166-178.	4.5	53
131	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. Histopathology, 2015, 67, 529-537.	2.9	37
132	<i>MED12</i> somatic mutations in fibroadenomas and phyllodes tumours of the breast. Histopathology, 2015, 67, 719-729.	2.9	78
133	Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. Journal of the National Cancer Institute, 2015, 108, djv427.	6.3	164
134	Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights. Journal of the National Cancer Institute, 2015, 107, .	6.3	80
135	Genomic landscape of adenoid cystic carcinoma of the breast. Journal of Pathology, 2015, 237, 179-189.	4.5	133
136	Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. Genome Biology, 2015, 16, 107.	8.8	109
137	A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumors. Modern Pathology, 2015, 28, 1603-1612.	5.5	100
138	Metastatic breast carcinomas display genomic and transcriptomic heterogeneity. Modern Pathology, 2015, 28, 340-351.	5.5	80
139	Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Modern Pathology, 2015, 28, 505-514.	5.5	180
140	Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival. PLoS ONE, 2014, 9, e114900.	2.5	77
141	PI3K Pathway Activation in High-Grade Ductal Carcinoma <i>In Situ</i> ê°'Implications for Progression to Invasive Breast Carcinoma. Clinical Cancer Research, 2014, 20, 2326-2337.	7.0	41
142	Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. Genome Biology, 2014, 15, 484.	8.8	117
143	Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity. Cell Reports, 2014, 6, 514-527.	6.4	239
144	Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. Journal of Pathology, 2014, 232, 553-565.	4.5	88

#	Article	IF	CITATIONS
145	Metaplastic breast carcinoma: more than a special type. Nature Reviews Cancer, 2014, 14, 147-148.	28.4	69
146	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nature Genetics, 2014, 46, 1166-1169.	21.4	188
147	Small cell carcinoma of the gynecologic tract: A multifaceted spectrum of lesions. Gynecologic Oncology, 2014, 134, 410-418.	1.4	79
148	Tackling the Diversity of Triple-Negative Breast Cancer. Clinical Cancer Research, 2013, 19, 6380-6388.	7.0	141
149	Adenoid cystic carcinomas constitute a genomically distinct subgroup of tripleâ€negative and basalâ€like breast cancers. Journal of Pathology, 2012, 226, 84-96.	4.5	144
150	The landscape of cancer genes and mutational processes in breast cancer. Nature, 2012, 486, 400-404.	27.8	1,535
151	Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. Histopathology, 2012, 60, E115-30.	2.9	52
152	Genetic Interactions in Cancer Progression and Treatment. Cell, 2011, 145, 30-38.	28.9	380
153	Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet, The, 2011, 378, 1812-1823.	13.7	629
154	Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics, 2011, 43, 879-882.	21.4	460
155	Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. Journal of Pathology, 2010, 220, 562-573.	4.5	185
156	Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. Journal of Pathology, 2010, 222, 282-298.	4.5	139
157	Breast cancer precursors revisited: molecular features and progression pathways. Histopathology, 2010, 57, 171-192.	2.9	286
158	Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. Modern Pathology, 2010, 23, 951-960.	5.5	56
159	Triple-Negative Breast Cancer. New England Journal of Medicine, 2010, 363, 1938-1948.	27.0	3,233
160	Histological types of breast cancer: How special are they?. Molecular Oncology, 2010, 4, 192-208.	4.6	365
161	Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncology, The, 2010, 11, 339-349.	10.7	318
162	Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice. Cancer Cell, 2009, 15, 294-303.	16.8	521

#	Article	IF	CITATIONS
163	Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?. Genes Chromosomes and Cancer, 2009, 48, 351-365.	2.8	80
164	Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Research and Treatment, 2009, 117, 273-280.	2.5	208
165	Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma. Histopathology, 2009, 55, 732-743.	2.9	48
166	Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Modern Pathology, 2009, 22, 1401-1414.	5.5	110
167	Histological and molecular types of breast cancer: is there a unifying taxonomy?. Nature Reviews Clinical Oncology, 2009, 6, 718-730.	27.6	353
168	Are triple-negative tumours and basal-like breast cancer synonymous?. Breast Cancer Research, 2007, 9, 404; author reply 405.	5.0	98
169	Prediction of <i>BRCA1</i> Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype. Clinical Cancer Research, 2005, 11, 5175-5180.	7.0	577